2. Search Result
Search Result
Results for "

Levodopa

" in MedChemExpress (MCE) Product Catalog:

11

Inhibitors & Agonists

3

Natural
Products

4

Isotope-Labeled Compounds

Cat. No. Product Name Target Research Areas Chemical Structure
  • HY-N0304
    L-DOPA
    Maximum Cited Publications
    13 Publications Verification

    Levodopa; 3,4-Dihydroxyphenylalanine

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease Cancer
    L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
    L-<em>DOPA</em>
  • HY-116016A
    Etilevodopa hydrochloride

    L-DOPA ethyl ester hydrochloride; Levodopa ethyl ester hydrochloride

    		 Dopamine Receptor Drug Metabolite Neurological Disease
    Etilevodopa (L-Dopa ethyl ester) hydrochloride, an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa hydrochloride is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .
    Etilevodopa hydrochloride
  • HY-116016
    Etilevodopa

    L-DOPA ethyl ester; Levodopa ethyl ester

    		 Dopamine Receptor Drug Metabolite Neurological Disease
    Etilevodopa (L-Dopa ethyl ester), an ethyl-ester proagent of Levodopa, is rapidly hydrolyzed to Levodopa and ethanol by nonspecific esterases in the gastrointestinal tract. Etilevodopa is used for the treatment of Parkinson disease (PD). Levodopa is the direct precursor of dopamine and is a suitable proagent as it facilitates CNS penetration and delivers dopamine .
    Etilevodopa
  • HY-N0304A
    L-DOPA sodium

    Levodopa sodium; 3,4-Dihydroxyphenylalanine sodium

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease
    L-DOPA (Levodopa) sodium is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA sodium can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA sodium has anti-allodynic effects, and can be used for Parkinson's disease research .
    L-<em>DOPA</em> sodium
  • HY-N0304R
    L-DOPA (Standard)

    Levodopa (Standard); 3,4-Dihydroxyphenylalanine (Standard)

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease Cancer
    L-DOPA (Standard) is the analytical standard of L-DOPA. This product is intended for research and analytical applications. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
    L-<em>DOPA</em> (Standard)
  • HY-N0304S
    L-DOPA-d6

    Levodopa-d6; 3,4-Dihydroxyphenylalanine-d6

    		 Dopamine Receptor Endogenous Metabolite Neurological Disease
    L-DOPA-d6 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[1][2][3].
    L-<em>DOPA</em>-d6
  • HY-N0304S1
    L-DOPA-13C6

    Levodopa-13C6; 3,4-Dihydroxyphenylalanine-13C6

    		 Dopamine Receptor Endogenous Metabolite
    L-DOPA- 13C6 is the 13C-labled L-DOPA . L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease .
    L-<em>DOPA</em>-13C6
  • HY-14859
    Dipraglurant

    ADX48621

    		 mGluR Neurological Disease
    Dipraglurant (ADX48621) is a potent, selective, orally active and brain penetrant mGluR5 negative allosteric modulator (NAM), with an IC50 of 21 nM. Dipraglurant can reduce Levodopa-induced dyskinesia (LID) in vivo . Dipraglurant is a click chemistry reagent, it contains an Alkyne group and can undergo copper-catalyzed azide-alkyne cycloaddition (CuAAc) with molecules containing Azide groups.
    Dipraglurant
  • HY-33549
    α-Methyl-p-tyrosine

    α-Methyl-p-tyrosine is a competitive inhibitor of the enzyme tyrosine hydroxylase, which converts tyrosine to Levodopa (DOPA). α-Methyl-p-tyrosine is an orally active inhibitor of catecholamine synthesis which inhibits the hydroxylation of tyrosine to DOPA .
    α-Methyl-p-tyrosine
  • HY-132392S
    L-DOPA-2,5,6-d3

    		Dopamine Receptor Endogenous Metabolite Neurological Disease
    L-DOPA-2,5,6-d3 is the deuterium labeled L-DOPA. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain[1][2][3].
    L-<em>DOPA</em>-2,5,6-d3
  • HY-N0304S2
    L-DOPA-13C
    1 Publications Verification

    		 Dopamine Receptor Endogenous Metabolite
    L-DOPA- 13C is the 13C labeled L-DOPA[1]. L-DOPA (Levodopa) is an orally active metabolic precursor of neurotransmitters dopamine. L-DOPA can cross the blood-brain barrier and is converted into dopamine in the brain. L-DOPA has anti-allodynic effects and the potential for Parkinson's disease[2][3][4].
    L-<em>DOPA</em>-13C

Inquiry Online

Your information is safe with us. * Required Fields.

Salutation

  

Country or Region *

Applicant Name *

 

Organization Name *

Department *

     

Email Address *

 

Product Name *

Cat. No.

  

Requested quantity *

Phone Number *

     

Remarks

Inquiry Online

Inquiry Information

Product Name:
Cat. No.:
Quantity:
MCE Japan Authorized Agent: